Dermata Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.31 M

Shareholding (Mar 2025)

FII

0.02%

Held by 1 FIIs

DII

99.61%

Held by 0 DIIs

Promoter

0.00%

How big is Dermata Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Dermata Therapeutics, Inc. has a market capitalization of 4.51 million, with net sales of 0.00 million and a net profit of -11.45 million over the last four quarters. The company reported shareholder's funds of 1.56 million and total assets of 3.53 million as of Dec 24.

What does Dermata Therapeutics, Inc. do?

22-Jun-2025

Dermata Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $4.51 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -156.92%.

Is Dermata Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, Dermata Therapeutics, Inc. shows a mildly bullish technical trend, supported by bullish MACD and KST indicators, but tempered by bearish moving averages and Bollinger Bands, while significantly underperforming the S&P 500 with year-to-date and one-year returns of -57.56% and -74.53%, respectively.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.15

Return on Equity

-183.97%

Price to Book

0.64

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-46.74%

6 Months

-60.23%

1 Year

-76.86%

2 Years

-97.51%

3 Years

989.49%

4 Years

-99.95%

5 Years

-84.71%

Dermata Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Dermata Therapeutics, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend for Dermata Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The MACD is mildly bullish on both weekly and monthly time frames, while the KST also shows a mildly bullish stance in the same periods. However, the moving averages indicate a bearish trend on the daily chart, and both the Bollinger Bands and Dow Theory are bearish on the monthly time frame. The RSI shows no signal on both weekly and monthly charts. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -57.56% versus the S&P 500's 12.22%, and a one-year return of -74.53% compared to 17.14% for the index. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators in other metrics....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-15.96%

EBIT to Interest (avg)

-10.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.33

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.79%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.65

EV to EBIT

0.43

EV to EBITDA

0.43

EV to Capital Employed

2.05

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

481.77%

ROE (Latest)

-156.92%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 1 Schemes (0.37%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 39.29% vs -64.71% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-2.90",
          "chgp": "37.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-2.80",
          "chgp": "39.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -57.69% vs 18.75% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.50",
          "val2": "-8.00",
          "chgp": "-56.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.30",
          "val2": "-7.80",
          "chgp": "-57.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.80

-2.90

37.93%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.70

-2.80

39.29%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 39.29% vs -64.71% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-12.50

-8.00

-56.25%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-12.30

-7.80

-57.69%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -57.69% vs 18.75% in Dec 2023

All Annual Results

Company CV

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Dermata Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Dermata Therapeutics, Inc.?

Watch in Real-Time

What does Dermata Therapeutics, Inc. do?

Is Dermata Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Dermata Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Dermata Therapeutics, Inc.

Company Coordinates